Vitamin D Compounds and Renal Osteodystrophy

Abstract

Get full access to this article

View all access options for this article.

References

Llach

, Felsenfeld

A.J.

, Coleman

.: Renal osteodystrophy in 131 unselected hemodialysis patients. American Society of Nephrology, Abstracts, 1983 (In Press). By the time of publication may have the exact reference.

Dent

C.E.

, Harper

C.M.

, Philpot

G.R.

: The treatment of renal-glomerular osteodystrophy. Q. J. Med., 30, 1–31, 1961.

Stanbury

S.W.

, Lumb

G.A.

: Metabolic studies of renal osteodystrophy: I. Calcium, phosphorus and nitrogen metabolism in rickets, osteomalacia, and hyperparathyroidism complicating chronic uremia and in the osteomalacia of the adult Fanconi syndrome. Medicine, 41, 1–30, 1962.

Verbeckmoes

, Bouillon

, Krempien

: Osteodystrophy of dialyzed patients treated with vitamin D. Proc. Eur. Dial. Transplant Assoc., 10, 217–225, 1973.

Cordy

P.E.

, Mills

D.M.

: The early detection and treatment of renal osteodystrophy. Min. Elec. Metab., 5, 311–320, 1981.

Ahmed

K.Y.

, Wills

M.R.

, Skinner

R.K.

.: Persistent hypophosphatemia and osteomalacia in dialysis patients not on oral phosphate binders: Response to dihydrotachysterol therapy. Lancet 2, 439–442, 1976.

Bordier

P.J.

, Marie

P.J.

, Arnaud

C.D.

: Evolution of renal osteodystrophy: Correlation of bone histomorphometry and serum mineral and immunoreactive parathyroid hormone values before and after treatment with calcium carbonate or 25-hydroxy-cholecalciferol. Kidney Int. Suppl., 7, 102–112, 1975.

Cournot-Witmer

, Margolis

, Fontaine

.: Effects of 25-hydroxy cholecalciferol on bone lesions of children with terminal renal failure. Kidney Int., 10: 395–408, 1976.

Frost

H.M.

, Griffith

D.L.

, Ju

W.S.

.: Histomorphometric changes in trabecular bone of renal failure patients treated with calcifediol. Metab. Bone Dis. Rel. Res. 2, 285–295, 1981.

10.

Birge

S.J.

, Haddad

J.G.

: 25-hydroxycholecalciferol stimulation of muscle metabolism. J. Clin. Invest., 56, 1100–1107, 1975.

11.

Goldstein

D.A.

, Malluche

H.H.

, Massry

S.G.

: Management of renal osteodystrophy with 1,25(OH)₂D₃: I. Effects on clinical, radiographic, and biochemical parameters. Min. Elec. Metab., 2, 35–47, 1979.

12.

Pierides

A.M.

, Ward

M.K.

, Alvarez-Ude

.: Long-term therapy with 1,25(OH)₂D₃ in dialysis bone disease. Proc. Eur. Dial. Transplant Assoc., 12, 237–244, 1975.

13.

Hodsman

A.B.

, Sherrard

D.J.

, Wong

E.G.C.

.: Vitamin D-resistant osteomalacia in hemodialysis patients lacking secondary hyperparathyroidism. Ann. Intern. Med. 94, 629–637, 1981.

14.

Chertow

B.S.

, Baylink

D.J.

, Wergedal

J.E.

.: Decrease in serum immunoreactive parathyroid hormone in rats and parathyroid hormone secretion in vitro by 1,25-dihydroxycholecalciferol. J. Clin. Invest, 56, 668–675, 1975.

15.

Kanis

J.A.

, Cundy

, Earnshaw

.: Treatment of renal bone disease with 1 alpha-hydroxylated derivatives of vitamin D3. Q. J. Med., 48: 289–322, 1979.

16.

Nielsen

H.E.

, Romer

F.K.

, Melsen

. 1 αhydroxyvitamin D₃ treatment of non-dialyzed patients with chronic renal failure: Effects on bone, mineral metabolism, and kidney function. Clin. Nephrol, 13, 103–108, 1980.

17.

Healy

M.D.

, Malluche

H.H.

, Goldstein

D.A.

.: Effects of long-term therapy with calcitriol in patients with moderate renal failure. Arch. Intern. Med., 140, 1030–1033, 1980.

18.

Kanis

J.A.

, Cundy

, Bartlett

.: Is 24,25-dihydroxycholecalciferol a calcium regulating hormone in man? Br. Med. J., 1, 1382–1386, 1978.

19.

Canterbury

J.M.

, Gavellas

, Bourgoigne

J.J.

.: Metabolic consequences of oral administration of 24,25-dihydroxycholecalciferol to uremic dogs. J. Clin. Invest., 65, 571–576, 1980.

20.

Hodsman

A.B.

, Wong

E.G.C.

, Sherrard

D.J.

.: Preliminary trials with 24,25-dihydroxyvitamin D₃ in dialysis osteomalacia. Am. J. Med., 74, 407–414, 1983.

21.

Brown

D.J.

, Dawborn

J.K.

, Ham

K.N.

.: Treatment of dialysis osteomalacia with deferrioxamine. Lancet 1, 343–345, 1982.